Johnson & Johnson's CEO believes the company will maintain its strong reputation for innovation amid changing economic conditions because of its hefty investments in research and development. He said it's crucial to invest both internally and externally, as some of the most innovative and lucrative opportunities come from outside companies.
We need to embrace principles from the tech industry and incorporate lessons learned from the pandemic to address the challenges of R&D productivity in pharma.
Cho discusses Bristol Myers Squibb’s research efforts in the field of protein degradation to advance potential treatments for a broad range of diseases. In a recent MedCity Pivot Podcast, he also shared insights on his approach to drug discovery, perspectives on dealing with failure, and some of the work his teams are doing in the COVID-19 space.
The drug industry maintains that policies like foreign reference pricing and letting Medicare negotiate prices would harm innovation. But closer examination reveals that while there is truth to that claim, it's more complex than it appears at first glance.
Red and blue states alike are ushering in new drug price legislation, building momentum while the federal government sits on its hands. What is the likely impact of these efforts on the industry?
A startup emerges from stealth mode to launch a new life sciences search engine to make the selection of reagents and equipment faster, more accurate and cost effective.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
We live in a golden age of medicine. Never before have so many effective treatment options been available to so many people. And precision medicine is bringing new horizons, as well as the promise to further improve disease prevention, treatment, and ultimately find more cures. To keep moving toward personalized medicine approaches, more individuals would […]
Collaboration, even with competitors, helps usher a drug into successful development, a new report from Deloitte released at this week's BIO convention says.
New York City’s working hard to position itself as a key life sciences hub. Citing the city’s many hospitals and deep history of medical innovation, the initiative just announced that it is expanding its Early-Stage Life Sciences Funding Initiative. It’s a $150 million public-private economic development effort that plans to up the city’s allocated R&D space by 150 […]
The pharma industry just got a hell of a lot nerdier, thanks to a recent Forbes op-ed. It likens the maze-like research and development quagmire to the elf-infused quests seen in fantasy role-playing game Dungeons and Dragons. Chances are slim for biotechs to make it through the high-stakes R&D game alive. Same goes for the goblins of D&D. The story goes: Dungeons […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
